The goal is to develop a standardized education and credentialing process for healthcare personnel and to generate tools and resources to help pregnant women make prenatal genetic testing decisions.
The firm has screened over 71,000 patients and identified more than 3,000 carriers, up to 25 percent of whom would have been missed with traditional screening tests.
Sequenom CEO Bill Welch said at the JP Morgan Healthcare Conference that the company plans to bring "at least" three new laboratory-developed tests to market in 2015.
The company's goal is to transition from a one-test provider to a full-service genetic testing company in the reproductive health and potentially other markets.
The partnership will enable Good Start to offer IviGen products and services to in vitro fertilization specialists and women's health professionals in the US and Canada.
